Nexium Antitrust Litigation
Court: United States District Court, District of Massachusetts
Leadership Position: Co-Lead Class Counsel
Wexler Wallace LLP, along with its co-counsel, filed a case on behalf of a class of end-payors (i.e., consumers and third-party payors, such as employee benefit funds and insurers) against AstraZeneca for allegedly entering into non-competition agreements with a number of generic pharmaceutical manufacturers in order to delay market entry of generic versions of its blockbuster drug Nexium.
According to the complaint, filed November 28, 2012, AstraZeneca agreed to pay generic defendants, Ranbaxy Pharmaceuticals, Teva Pharmaceuticals, and Dr. Reddy’s Laboratories, substantial sums in exchange for their agreement to delay marketing of generic Nexium for six years or more. The complaint alleges that without these delays, cheaper generic versions of the drug would have entered the market as early as April 14, 2008.
For a copy of the complaint, click here.